4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 341.96 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 21.28K shares, a 107.21% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 320.68K shares, a 1213.19% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 574.74K shares, a 2132.79% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 43.43K shares, a 1597.65% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 652.86K shares, a 1658.02% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 37.14K shares, a 71.25% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 129.15K shares, a 18.58% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 108.91K shares, a 2418.80% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 21.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 341.96K shares 10-Q · filed 2026-08-13 | 916.71K shares derived: sum of 3 quarters · filed 2026-08-13 | 960.13K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 320.68K shares 10-Q · filed 2026-05-07 | 895.42K shares derived: sum of 2 quarters · filed 2026-05-07 | 938.85K shares derived: sum of 3 quarters · filed 2026-05-07 | 949.12K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 574.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | 618.17K shares derived: sum of 2 quarters · filed 2026-03-18 | 628.44K shares derived: sum of 3 quarters · filed 2026-03-18 | 652.86K shares 10-K · filed 2026-03-18 |
| 2025-09-30 | 43.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 53.70K shares derived: sum of 2 quarters · filed 2025-11-10 | 78.12K shares 10-Q · filed 2025-11-10 | 103.86K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 10.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 34.69K shares 10-Q · filed 2025-08-11 | 60.43K shares derived: sum of 3 quarters · filed 2025-08-11 | 62.99K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 24.42K shares 10-Q · filed 2025-05-08 | 50.16K shares derived: sum of 2 quarters · filed 2025-05-08 | 52.72K shares derived: sum of 3 quarters · filed 2025-05-08 | 54.48K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 25.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 28.30K shares derived: sum of 2 quarters · filed 2025-02-28 | 30.05K shares derived: sum of 3 quarters · filed 2025-02-28 | 37.14K shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 2.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 4.31K shares derived: sum of 2 quarters · filed 2024-11-13 | 11.39K shares 10-Q · filed 2024-11-13 | 79.80K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 1.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 8.84K shares 10-Q · filed 2024-08-08 | 77.24K shares derived: sum of 3 quarters · filed 2024-08-08 | 119.72K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 7.08K shares 10-Q · filed 2024-05-09 | 75.48K shares derived: sum of 2 quarters · filed 2024-05-09 | 117.97K shares derived: sum of 3 quarters · filed 2024-05-09 | 129.49K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 68.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 110.89K shares derived: sum of 2 quarters · filed 2024-02-29 | 122.41K shares derived: sum of 3 quarters · filed 2024-02-29 | 129.15K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 42.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 54.01K shares derived: sum of 2 quarters · filed 2023-11-09 | 60.75K shares 10-Q · filed 2023-11-09 | 87.03K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 11.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 18.26K shares 10-Q · filed 2023-08-09 | 44.55K shares derived: sum of 3 quarters · filed 2023-08-09 | 71.73K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 6.74K shares 10-Q · filed 2023-05-11 | 33.02K shares derived: sum of 2 quarters · filed 2023-05-11 | 60.21K shares derived: sum of 3 quarters · filed 2023-05-11 | 43.92K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 26.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 53.48K shares derived: sum of 2 quarters · filed 2023-03-15 | 37.18K shares derived: sum of 3 quarters · filed 2023-03-15 | 108.91K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 27.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 10.89K shares derived: sum of 2 quarters · filed 2022-11-08 | 82.63K shares 10-Q · filed 2022-11-08 | 86.60K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | -16.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 55.44K shares 10-Q · filed 2022-08-11 | 59.41K shares derived: sum of 3 quarters · filed 2022-08-11 | |
| 2022-03-31 | 71.73K shares 10-Q · filed 2022-05-12 | 75.70K shares derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | 3.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 4.32K shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 354.00 shares 10-Q · filed 2021-11-10 | |||
| 2020-12-31 | 103.64K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |